| CELLECTIS NOM. EO-,05 |
| Frankreich |
| Gesundheit |
| FR0010425595 / A0MKPR |
| ZVA (Frankfurt) |
| FRA:ZVA, ETR:ZVA, ZVA:GR |
| - |
| https://www.cellectis.com.. |
|
Cellectis S.A. is a clinical-stage biotechnology company focused on gene editing and cell therapy. The company develops allogeneic CAR T-cell product candidates designed for immuno-oncology, along with gene-edited therapies for other serious diseases..
>Volltext.. |
| 190.67 Mio. EUR |
| 135.9 Mio. EUR |
| 47.72 Mio. EUR |
| -39.19 Mio. EUR |
| -55.2 Mio. EUR |
| -0.55 EUR |
| 89.81 Mio. EUR |
| 30.79 Mio. EUR |
| -35.05 Mio. EUR |
| 1.24 |
| -5.98% |
| -4.58% |
| - |
| - |
| - |
| - |
| CELLECTIS |
| 15.09.26 |
|